Do analysts prefer DXST or KRKR?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Decent 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 36Kr 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation and earnings, DXST or KRKR?

36Kr has higher revenue and earnings than Decent. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Decent $12.95M 0.35 -$320K N/A N/A 36Kr $32.59M 0.21 $1.55M -$6.00 N/A

Is DXST or KRKR more profitable?

Company Net Margins Return on Equity Return on Assets Decent N/A N/A N/A 36Kr N/A N/A N/A

Do analysts rate BIAF or DXST?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score bioAffinity Technologies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Decent 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings & valuation, BIAF or DXST?

Decent has higher revenue and earnings than bioAffinity Technologies. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio bioAffinity Technologies $5.61M 1.33 -$14.91M -$11.77 N/A Decent $12.95M 0.35 -$320K N/A N/A

Does the media favor BIAF or DXST?

In the previous week, Decent had 4 more articles in the media than bioAffinity Technologies. MarketBeat recorded 6 mentions for Decent and 2 mentions for bioAffinity Technologies. bioAffinity Technologies' average media sentiment score of 1.31 beat Decent's score of 0.73 indicating that bioAffinity Technologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment bioAffinity Technologies 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Decent 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer FTFT or DXST?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Future FinTech Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Decent 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings & valuation, FTFT or DXST?

Decent has higher revenue and earnings than Future FinTech Group. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Future FinTech Group $3.50M 1.87 -$4.62M -$3.17 N/A Decent $12.95M 0.35 -$320K N/A N/A

Do analysts recommend OLB or DXST?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score OLB Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Decent 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings and valuation, OLB or DXST?

Decent has higher revenue and earnings than OLB Group. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio OLB Group $8.68M 0.76 -$5.87M -$0.87 N/A Decent $12.95M 0.35 -$320K N/A N/A

Is OLB or DXST more profitable?

Decent has a net margin of 0.00% compared to OLB Group's net margin of -73.19%. Decent's return on equity of 0.00% beat OLB Group's return on equity. Company Net Margins Return on Equity Return on Assets OLB Group -73.19% -96.26% -45.18% Decent N/A N/A N/A

Do analysts rate DXST or SYRA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Decent 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Syra Health 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better earnings & valuation, DXST or SYRA?

Decent has higher revenue and earnings than Syra Health. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Decent $12.95M 0.35 -$320K N/A N/A Syra Health $7.98M 0.83 -$2.94M -$0.02 N/A

Is DXST or SYRA more profitable?

Decent has a net margin of 0.00% compared to Syra Health's net margin of -54.90%. Decent's return on equity of 0.00% beat Syra Health's return on equity. Company Net Margins Return on Equity Return on Assets Decent N/A N/A N/A Syra Health -54.90% -131.94% -99.19%

Trading of Decent was halted at 09:38 AM EST due to "LULD Pause".

Decent (DXST) Competitors

$4.62 -0.33 (-6.67%)

As of 12:10 PM Eastern

Compare

DXST vs. KRKR, BIAF, FTFT, OLB, and SYRA

Should you buy Decent stock or one of its competitors? MarketBeat compares Decent with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Decent include 36Kr (KRKR), bioAffinity Technologies (BIAF), Future FinTech Group (FTFT), OLB Group (OLB), and Syra Health (SYRA). These companies are all part of the "business services" industry.

How does Decent compare to 36Kr?

Decent (NASDAQ:DXST) and 36Kr (NASDAQ:KRKR) are both small-cap business services companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, institutional ownership, valuation, dividends, earnings, profitability and media sentiment.

In the previous week, Decent had 5 more articles in the media than 36Kr. MarketBeat recorded 6 mentions for Decent and 1 mentions for 36Kr. 36Kr's average media sentiment score of 1.24 beat Decent's score of 0.73 indicating that 36Kr is being referred to more favorably in the news media.

Company	Overall Sentiment
Decent	Positive
36Kr	Positive

Company	Net Margins	Return on Equity	Return on Assets
Decent	N/A	N/A	N/A
36Kr	N/A	N/A	N/A

Decent has a beta of 0.35, indicating that its share price is 65% less volatile than the broader market. Comparatively, 36Kr has a beta of 0.46, indicating that its share price is 54% less volatile than the broader market.

0.1% of 36Kr shares are held by institutional investors. 39.4% of 36Kr shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

36Kr has higher revenue and earnings than Decent.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Decent	$12.95M	0.35	-$320K	N/A	N/A
36Kr	$32.59M	0.21	$1.55M	-$6.00	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Decent	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
36Kr	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

36Kr beats Decent on 6 of the 8 factors compared between the two stocks.

How does Decent compare to bioAffinity Technologies?

bioAffinity Technologies (NASDAQ:BIAF) and Decent (NASDAQ:DXST) are both small-cap business services companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, valuation, dividends, profitability, earnings, institutional ownership and risk.

bioAffinity Technologies has a beta of -1.33, meaning that its stock price is 233% less volatile than the broader market. Comparatively, Decent has a beta of 0.35, meaning that its stock price is 65% less volatile than the broader market.

1.6% of bioAffinity Technologies shares are held by institutional investors. 2.7% of bioAffinity Technologies shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Decent has higher revenue and earnings than bioAffinity Technologies.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
bioAffinity Technologies	$5.61M	1.33	-$14.91M	-$11.77	N/A
Decent	$12.95M	0.35	-$320K	N/A	N/A

In the previous week, Decent had 4 more articles in the media than bioAffinity Technologies. MarketBeat recorded 6 mentions for Decent and 2 mentions for bioAffinity Technologies. bioAffinity Technologies' average media sentiment score of 1.31 beat Decent's score of 0.73 indicating that bioAffinity Technologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
bioAffinity Technologies	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Decent	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
bioAffinity Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Decent	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Decent has a net margin of 0.00% compared to bioAffinity Technologies' net margin of -280.53%. Decent's return on equity of 0.00% beat bioAffinity Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
bioAffinity Technologies	-280.53%	-285.75%	-143.71%
Decent	N/A	N/A	N/A

Summary

Decent beats bioAffinity Technologies on 7 of the 11 factors compared between the two stocks.

How does Decent compare to Future FinTech Group?

Future FinTech Group (NASDAQ:FTFT) and Decent (NASDAQ:DXST) are both small-cap business services companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, earnings, risk, media sentiment and valuation.

Future FinTech Group has a beta of 1.77, indicating that its stock price is 77% more volatile than the broader market. Comparatively, Decent has a beta of 0.35, indicating that its stock price is 65% less volatile than the broader market.

Decent has higher revenue and earnings than Future FinTech Group.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Future FinTech Group	$3.50M	1.87	-$4.62M	-$3.17	N/A
Decent	$12.95M	0.35	-$320K	N/A	N/A

Decent has a net margin of 0.00% compared to Future FinTech Group's net margin of -37.76%. Decent's return on equity of 0.00% beat Future FinTech Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Future FinTech Group	-37.76%	-13.08%	-10.33%
Decent	N/A	N/A	N/A

0.2% of Future FinTech Group shares are held by institutional investors. 1.5% of Future FinTech Group shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Future FinTech Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Decent	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Decent had 4 more articles in the media than Future FinTech Group. MarketBeat recorded 6 mentions for Decent and 2 mentions for Future FinTech Group. Future FinTech Group's average media sentiment score of 1.44 beat Decent's score of 0.73 indicating that Future FinTech Group is being referred to more favorably in the media.

Company	Overall Sentiment
Future FinTech Group	Positive
Decent	Positive

Summary

Decent beats Future FinTech Group on 6 of the 11 factors compared between the two stocks.

How does Decent compare to OLB Group?

OLB Group (NASDAQ:OLB) and Decent (NASDAQ:DXST) are both small-cap business services companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, analyst recommendations, institutional ownership, dividends, profitability, earnings and risk.

OLB Group has a beta of 2.02, suggesting that its stock price is 102% more volatile than the broader market. Comparatively, Decent has a beta of 0.35, suggesting that its stock price is 65% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OLB Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Decent	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

3.8% of OLB Group shares are held by institutional investors. 60.2% of OLB Group shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Decent had 4 more articles in the media than OLB Group. MarketBeat recorded 6 mentions for Decent and 2 mentions for OLB Group. OLB Group's average media sentiment score of 0.96 beat Decent's score of 0.73 indicating that OLB Group is being referred to more favorably in the media.

Company	Overall Sentiment
OLB Group	Positive
Decent	Positive

Decent has higher revenue and earnings than OLB Group.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OLB Group	$8.68M	0.76	-$5.87M	-$0.87	N/A
Decent	$12.95M	0.35	-$320K	N/A	N/A

Decent has a net margin of 0.00% compared to OLB Group's net margin of -73.19%. Decent's return on equity of 0.00% beat OLB Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OLB Group	-73.19%	-96.26%	-45.18%
Decent	N/A	N/A	N/A

Summary

Decent beats OLB Group on 6 of the 11 factors compared between the two stocks.

How does Decent compare to Syra Health?

Decent (NASDAQ:DXST) and Syra Health (NASDAQ:SYRA) are both small-cap business services companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, dividends, earnings, valuation, profitability, risk and institutional ownership.

4.8% of Syra Health shares are owned by institutional investors. 24.6% of Syra Health shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Decent has a net margin of 0.00% compared to Syra Health's net margin of -54.90%. Decent's return on equity of 0.00% beat Syra Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Decent	N/A	N/A	N/A
Syra Health	-54.90%	-131.94%	-99.19%

Decent has higher revenue and earnings than Syra Health.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Decent	$12.95M	0.35	-$320K	N/A	N/A
Syra Health	$7.98M	0.83	-$2.94M	-$0.02	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Decent	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Syra Health	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Decent has a beta of 0.35, suggesting that its stock price is 65% less volatile than the broader market. Comparatively, Syra Health has a beta of 3.1, suggesting that its stock price is 210% more volatile than the broader market.

In the previous week, Decent had 6 more articles in the media than Syra Health. MarketBeat recorded 6 mentions for Decent and 0 mentions for Syra Health. Decent's average media sentiment score of 0.73 beat Syra Health's score of 0.00 indicating that Decent is being referred to more favorably in the media.

Company	Overall Sentiment
Decent	Positive
Syra Health	Neutral

Summary

Decent beats Syra Health on 8 of the 12 factors compared between the two stocks.

Get Decent News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DXST and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DXST vs. The Competition

Export

Metric	Decent	Waste Removal Svcs Industry	Business Sector	NASDAQ Exchange
Market Cap	$4.53M	$9.75B	$6.52B	$12.44B
Dividend Yield	N/A	1.12%	2.96%	5.30%
P/E Ratio	N/A	69.69	29.33	24.23
Price / Sales	0.35	35.33	412.95	126.08
Price / Cash	N/A	12.85	24.63	57.88
Price / Book	0.59	5.86	5.89	6.73
Net Income	-$320K	$387.83M	$203.37M	$336.97M
7 Day Performance	167.05%	5.74%	1.24%	0.79%
1 Month Performance	134.52%	1.22%	1.71%	5.38%
1 Year Performance	-86.31%	-4.64%	40.74%	34.55%

Decent Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DXST Decent	0.7885 of 5 stars	$4.62 -6.7%	N/A	-85.0%	$4.53M	$12.95M	N/A	16	News Coverage Gap Down Trading Halted
KRKR 36Kr	1.0788 of 5 stars	$3.63 flat	N/A	-37.6%	$7.15M	$32.59M	N/A	570	Gap Up
BIAF bioAffinity Technologies	0.4713 of 5 stars	$1.56 flat	N/A	-78.7%	$7.07M	$6.16M	N/A	10	News Coverage Gap Up
FTFT Future FinTech Group	1.0968 of 5 stars	$1.17 flat	N/A	-78.4%	$6.87M	$3.83M	N/A	70
OLB OLB Group	1.0565 of 5 stars	$0.47 flat	N/A	-77.2%	$6.86M	$8.68M	N/A	30

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DXST) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Decent (DXST) Competitors